Cyclo Therapeutics reported the appointment of Caroline Hastings, M.D. as Global Principal Investigator (PI) for its pivotal Phase 3 study TransportNPC), which commenced in June 2021, evaluating Trappsol Cyclo, the Company's proprietary formulation of hydroxypropyl beta cyclodextrin, for the treatment of Niemann-Pick Disease Type C1 (NPC), a rare, progressive and fatal genetic disorder. Dr. Caroline Hastings has been practicing in the field of Pediatric Hematology Oncology since 1992 and has served as the director of the fellowship program at the Children's Hospital & Research Center Oakland since 1996. She has devoted herself to her patients and to fostering education in this specialty.